|
|
|
|
|
|
Sponsored by: |
National Institute on Alcohol Abuse and Alcoholism (NIAAA) |
Information provided by: | National Institute on Alcohol Abuse and Alcoholism (NIAAA) |
ClinicalTrials.gov Identifier: | NCT00132795 |
The purpose of this study is to determine whether a telephone based self-help program will prevent relapse among individuals undergoing standard substance abuse treatment.
Condition | Intervention | Phase |
Alcoholism |
Behavioral: Daily monitoring of alcohol & drug use, & therapy skills Device: Alcohol Therapeutic Interactive Voice Response System |
Phase II |
MedlinePlus related topics: | Alcoholism |
Drug Information available for: | Ethanol |
Study Type: | Interventional |
Study Design: | Other, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study |
Official Title: | Therapeutic IVR to Augment CBT in Alcohol Dependence |
Estimated Enrollment: | 200 |
Study Start Date: | May 2005 |
Estimated Study Completion Date: | December 2009 |
Estimated Primary Completion Date: | December 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
1 Therapeutic Phone System: Active Comparator
Comparison(s): patients completing group CBT for substance abuse will be randomly assigned to two conditions. In one condition, patients will have unlimited access to the therapeutic telephone system for 4 months. The other condition is standard care (i.e., no formal relapse prevention).
|
Device: Alcohol Therapeutic Interactive Voice Response System
Patients will have unlimited access to the therapeutic telephone system for 4 months.
|
2 Standard care: Active Comparator
Comparison(s): patients completing group CBT for substance abuse will be randomly assigned to two conditions. In one condition, patients will have unlimited access to the therapeutic telephone system for 4 months. The other condition is standard care (i.e., no formal relapse prevention).
|
Behavioral: Daily monitoring of alcohol & drug use, & therapy skills
Comparison(s): patients completing group CBT for substance abuse will be randomly assigned to two conditions. In one condition, patients will have unlimited access to the therapeutic telephone system for 4 months. The other condition is standard care (i.e., no formal relapse prevention).
|
Relapse rates in the first few months following substance abuse treatment are as high as 50%, in spite of the immediate effectiveness of treatments such as Cognitive Behavioral Therapy (CBT). Continuing use of therapy skills following treatment is associated with maintenance of treatment gains. We have programmed a telephone to deliver pre-recorded summaries and rehearsal sessions of skills learned in therapy. The system also includes monthly feedback messages from therapists. We expect that this ad-lib access to therapy skills would allow patients to generalize skills to their personal post-treatment lives. It would also allow individuals in remote or rural areas to obtain access to assistance without travel barriers.
Comparison(s): patients completing group CBT for substance abuse will be randomly assigned to two conditions. In one condition, patients will have unlimited access to the therapeutic telephone system for 4 months. The other condition is standard care (i.e., no formal relapse prevention).
Ages Eligible for Study: | 19 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Gail L. Rose, Ph.D. | 802-847-1430 | Gail.Rose@vtmednet.org |
United States, Vermont | |||||
UVM Health Behavior Research Center | Recruiting | ||||
South Burlington, Vermont, United States, 05403 | |||||
Contact: Gail L. Rose, Ph.D. 802-847-1430 Gail.Rose@vtmednet.org | |||||
Principal Investigator: John E. Helzer, MD |
Principal Investigator: | John E. Helzer, MD | University of Vermont |
Responsible Party: | The University of Vermont ( John E. Helzer, M.D., Principal Investigator ) |
Study ID Numbers: | NIAAAHEL014270, NIH Grant 5 R01 AA014270-02 |
First Received: | August 19, 2005 |
Last Updated: | September 26, 2008 |
ClinicalTrials.gov Identifier: | NCT00132795 |
Health Authority: | United States: Federal Government |
|
|
|